Oramed Pharmaceuticals Statistics Share Statistics Oramed Pharmaceuticals has 40.82M
shares outstanding. The number of shares has increased by 0.2%
in one year.
Shares Outstanding 40.82M Shares Change (YoY) 0.2% Shares Change (QoQ) 1.34% Owned by Institutions (%) 19% Shares Floating 32.56M Failed to Deliver (FTD) Shares 1,609 FTD / Avg. Volume 2%
Short Selling Information The latest short interest is 348.14K, so 0.85% of the outstanding
shares have been sold short.
Short Interest 348.14K Short % of Shares Out 0.85% Short % of Float 0.97% Short Ratio (days to cover) 4.16
Valuation Ratios The PE ratio is -5.17 and the forward
PE ratio is -1.9.
Oramed Pharmaceuticals's PEG ratio is
0.01.
PE Ratio -5.17 Forward PE -1.9 PS Ratio 0 Forward PS n/a PB Ratio 0.68 P/FCF Ratio -11.72 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Oramed Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 25.19,
with a Debt / Equity ratio of 0.
Current Ratio 25.19 Quick Ratio 25.19 Debt / Equity 0 Debt / EBITDA -0.03 Debt / FCF -0.04 Interest Coverage -14.98
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.47M Employee Count 13 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 3.18M Effective Tax Rate -19.99%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.68, so Oramed Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.68 52-Week Price Change n/a 50-Day Moving Average 2.2 200-Day Moving Average 2.25 Relative Strength Index (RSI) 57.41 Average Volume (20 Days) 80,488
Income Statement
Revenue n/a Gross Profit -193K Operating Income -12.78M Net Income -19.1M EBITDA -14.87M EBIT -15.07M Earnings Per Share (EPS) -0.47
Full Income Statement Balance Sheet The company has 54.42M in cash and 372K in
debt, giving a net cash position of 54.05M.
Cash & Cash Equivalents 54.42M Total Debt 372K Net Cash 54.05M Retained Earnings -176.62M Total Assets 161.68M Working Capital 95.33M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -8.41M
and capital expenditures -18K, giving a free cash flow of -8.43M.
Operating Cash Flow -8.41M Capital Expenditures -18K Free Cash Flow -8.43M FCF Per Share -0.21
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ORMP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ORMP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 23, 2013. It was a
backward
split with a ratio of 1:12.
Last Split Date Jan 23, 2013 Split Type backward Split Ratio 1:12
Scores Altman Z-Score 6.23 Piotroski F-Score 2
